Weekly Recap: Enhertu CHMP backing for adjuvant HER2+ and Klygefa for gMG
AstraZeneca PLC (LSE:AZN) reported a string of clinical and regulatory wins—CHMP backing for Enhertu in early HER2+ breast cancer and for Klygefa in gMG, positive data for Trixeo and 14 China licensing deals—yet shares slipped amid the announcements, trading down to 12,550p/12,450p.Previous Week Re…